Reunion Neuroscience Inc - REUN - Share chat

This firm develops novel psychedelic drugs, committed to innovating therapeutic solutions for mental health conditions. Its lead asset, RE-104, is being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant.

Is this a cannabis related stock or do they work with psychedelic mushrooms as well?